The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells

European Journal of Haematology

Volumn 72, Issue 6, 2004, Pages 420-429

  Baśkiewicz Masiuk, Magdalena ^a   Machaliński, Boguslław ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

AML; Antisense oligodeoxynucleotides; Apoptosis; CML; Leukaemogenesis; STAT5

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; METHYLCELLULOSE; PROTEIN SUBUNIT; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; APOPTOSIS; CELL DIVISION; CLONE CELLS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MILK PROTEINS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; STAT5 TRANSCRIPTION FACTOR; TIME FACTORS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 2542619062     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00242.x     Document Type: Article

References (41)

1. IMADA K, LEONARD WJ. The Jak-Stat pathway. Mol Immunol 2000;37:1-11.
2. AARONSON DS, HORVATH CM. A road map for those who don't know JAK-STAT. Science 2002;296:1653-1655.
3. BOWMAN T, GARCIA R, TURKSON J, JOVE R. STATs in oncogenesis. Oncogene 2000;19:2474-2488.
4. GRIMLEY PM, DONG F, RUI H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 1999;10:131-157.
5. AKIRA S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells (Dayt) 1999;17:138-146.
6. CHAKABORTY A, DYER KF, TWEARDY DJ. Delineation and mapping of STAT5 isoforms activated by granulocyte colony-stimulating factor in myeloid cells. Blood Cells Mol Dis 2000;26:320-330.
7. NOSAKA T, KAWASHIMA T, MISAWA K, IKUTA K, MUI A, KITAMURA T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 1999;18:4754-4759.
8. WARD A, TOUW I, YOSHIMURA A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95:19-26.
9. SHUAI K, HALPERN J, HOEVE J, RAO X, SAWYERS CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-254.
10. BENEKLI M, BAER MR, BAUMANN H, WETZLER M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003;101:2940-2954.
11. GOUILLEUX-GRUART V, GOUILLEUX F, DESAINT C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996;87:1692-1697.
12. SCHWALLER J, PARGANAS E, WANG D, et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 2000;6:693-704.
13. LEONG PL, XI S, DRENNING SD, DYER KF, WENTZEL AL, LERNAR EC, SMITHGALL TE, GRANDIS JR. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 2002;21:2846-2853.
14. HAYAKAWA F, TOWATARI M, IIDA H, WAKAO H, KIYOI H, NAOE T, HIDEHIKO S. Differential constitutive activation between STAT-related and neutrophil proteins and MAP kinase in primary acute myelogenous leukemia. Br J Haematol 1998;101:521-528.
15. WEBER-NORDT RM, MERTELSMANN R, FINKE J. The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leuk Lymphoma 1998;28:459-467.
16. MACHALIŃSKI B, SZOLOMICKA P, KIJOWSKI J, BAŚKIEWICZ M, KARBICKA A, BYRA E, MAJKA M, GIEDRYS-KALEMBA S, RATAICZAK MZ. Short-term storage of human haematopoietic cells. Influence of air and deoxyribonuclease. Ann Transplant 1999;4:29-36.
17. RATAJCZAK MZ, LUGER SM, DERIEL K, ABRAHM J, CALABRETTA B, GEWIRTZ AM. Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci USA 1992;89:1710-1714.
18. SCHURINGA JJ, WIERENGA ATJ, KRUIJER W, VELLENGA E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000;95: 3765-3770.
19. BAŚKIEWICZ-MASIUK M, MASIUK M, CZAJKA R, MACHALIŃSKI B. The role of STAT5 proteins in the regulation of normal hematopoiesis in a cord blood model. Cell Mol Biol Lett 2003;8:317-331.
20. BAŚKIEWICZ-MASIUK M, MASIUK M, MACHALIŃSKI B. The influence of STAT5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukaemic cell lines. Cell Prolif 2003;36:265-278.
21. MAJKA M, RATAJCZAK J, MACHALIŃSKI B, CARTER A, PIZZINI D, WA̧SIK MA, GEWIRTZ AM, RATAJCZAK MZ. Expression, regulation and function of AC133, a putative human haematopoietic cells. Folia Histochem Cytobiol 2000;38:53-63.
22. LUGER SM, O'BRIEN SG, RATAJCZAK J, RATAJCZAK MZ, MICK R, STADTMAUER EA, NOWELL PC, GOLDMAN JM, GEWIRTZ AM. Oligodeoxynucleotide-mediated inhibition of c-myc gene expression in autografted bone marrow: a pilot study. Blood 2002;99:1150-1158.
23. GESBERT F, GRIFFIN JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000;96:2269-2276.
24. RATAJCZAK J, KUCIA M, RECA R, ZHANG J, MACHALIŃSKI B, RATAJCZAK MZ. Quiescent CD34+ early erythroid progenitors are resistant to several erythropoietic 'inhibitory' cytokines; role of FLIP. Br J Haematol 2003;123:160-169.
25. KIESLINGER M, WOLDMAN I, MORIGGL R, HOFMANN J, MARINE JC, IHLE JN, BEUG H, DECKER T. Antiapoptotic activity of STAT5 required during terminal stages of myeloid differentiation. Genes Dev 2000;14:232-244.
26. KOOPMAN G, REUTELINGSPERGER CP, KUIJTEN GA, KEEHNEN RM, PALS ST, van OERS MH. Annexin V for flow cytometic detection of phosphatidyl-serine expression on B cells undergoing apoptosis. Blood 1994;84:1415-1420.
27. MOULIAN N, TRUFFAULT F, GAUDRY-TALARMAIN YM, SERRAF A, BERRIH-AKNIN S. In vivo and in vitro apoptosis of human thymocytes are associated with nitrotyrosine formation. Blood 2001;97:3521-3530.
28. COFFER PJ, KOENDERMAN L, de GROOT RP. The role of STATs in myeloid differentiation and leukemia. Oncogene 2000;19:2511-2522.
29. RATAJCZAK MZ, GEWIRTZ AM. Oligonucleotide-based therapeutics of human malignancies. Nucleic Acids Mol Biol 1994;8:298-321.
30. BAŚKIEWICZ-MASIUK M, PACZKOWSKI M, MACHALIŃSKI B. The influence of antisense oligonucleotides against STAT5 on the regulation of normal haematopoiesis in a bone marrow model. Cell Prolif 2004;37 (in press).
31. de GROOT RP, RAAIJMAKERS J, LAMMERS J, JOVE R, KOENDERMAN L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999;94:1108-1112.
32. SILLABER C, GESBERT F, FRANK DA, SATTLER M, GRIFFIN JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000;95:2118-2125.
33. SEXL V, PIEKORZ R, MORIGGL R, ROHRER J, BROWN MP, BUNTING KD, ROTHAMMER K, ROUSSEL MF, IHLE JN. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of StatS. Blood 2000;96:2277-2283.
34. SONOYAMA J, MATSUMURA I, EZOE S, et al. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 2002;277:8076-8082.
35. ILARIA RL, HAWLEY RG, VAN ETTEN RA. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 1999;93:4154-4166.
36. SPIEKERMANN K, PAU M, SCHWAB R, SCHMIEJA K, FRANZRAHE S, HIDDEMANN W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002;30:262-271.
37. BIRKENKAMP KU, GEUGIEN M, LEMMINK HH, KRUIJER W, VELLENGA E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blast. Leukemia 2001;15:1923-1931.
38. XIA Z, SAIT SN, BAER MR, BARCOS M, DONOHUE KA, LAWRENCE D, FORD LA, BLOCK AMW, BAUMANN H, WETZLER M. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res 2001;25:473-482.
39. SPIEKERMANN K, DIRSCHINGER RJ, SCHWAB R, BAGRINTSEVA K, FABER F, BUSKE C, SCHNITTGER S, KELLY LM, LILLILAND DG, HIDDEMANN W. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2003;101:1494-1504.
40. RAVANDI F, TALPAZ M, KANTARJIAN H, ESTROV Z. Cellular signaling pathways: new targets in leukaemia therapy. Br J Haematol 2002;116:57-77.
41. TURKSON J, JOVE R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-6626.